Subcutaneous Immunotherapy for Mouse in Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
AsthmaPerennial Allergic Rhinitis
Interventions
BIOLOGICAL

Mouse Allergenic Extract

Subjects will receive escalating doses of glycerinated mouse allergenic extract administered subcutaneously up to a maximum study dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol., per protocol.

Trial Locations (4)

20010

Children's National Health System, Washington D.C.

21287

Johns Hopkins Children's Center: Department of Allergy & Immunology, Baltimore

48202

Henry Ford Health System: Division of Allergy and Immunology, Detroit

60611

Ann and Robert Lurie Children's Hospital of Chicago, Chicago

All Listed Sponsors
collaborator

Inner-City Asthma Consortium

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02532179 - Subcutaneous Immunotherapy for Mouse in Adults | Biotech Hunter | Biotech Hunter